2010 Fiscal Year Final Research Report
Development of treatment algorithm for depressive disorders using genetic and biological markers
Project/Area Number |
19591366
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Psychiatric science
|
Research Institution | University of the Ryukyus |
Principal Investigator |
KONDO Tsuyoshi University of the Ryukyus, 医学研究科, 教授 (40215455)
|
Co-Investigator(Kenkyū-buntansha) |
MIHARA Kazuo 国立大学法人琉球大学, 医学部, 准教授 (30302029)
NAKAMURA AKifumi 国立大学法人琉球大学, 医学部附属病院, 助教 (40381222)
|
Project Period (FY) |
2007 – 2010
|
Keywords | うつ病性障害 / 気質性格因子 / 遺伝多型 / 抗うつ薬 / 気分安定薬 / 自殺関連事象 |
Research Abstract |
Genetic and biological markers to achieve efficient individualized pharmacotherapy of depressive disorders were investigated. Young females had higher scores in cyclothymic temperament, suggesting potential risk of antidepressant-induced mood switching in these subjects. Gene-dose effect of ^*10 allele of cytochrome P450 2D6 was apparent in the steady-state concentrations of aripiprazole. Lamotrigine augmentation in patients with treatment-resistant mood disorders resulted in reduced severity of depressive symptoms (-41.9%) and increased social functioning (+30.3%), showing better response especially in subjects with a shorter and frequent depressive episodes. Persisted suicide-related risks among teenagers under antidepressant therapy were closely associated with some clinical backgrounds (over 15 years of age, female and baseline self-destructive behaviors) and specific psychopathology (anhedonia, irritability, hopelessness, borderline personality disorder and psychotic features).
|
-
[Journal Article] Effects of CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole in Japanese patients with schizophrenia.2011
Author(s)
Suzuki T, Mihara K, Nakamura A, Nagai G, Kagawa S, Nemoto K, Ohta I, Arakaki G, Uno T, Kondo T
-
Journal Title
Therapeutic Drug Monitorong 33
Pages: 21-24
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-